Literature DB >> 25187727

High infiltration of tumor-associated macrophages in triple-negative breast cancer is associated with a higher risk of distant metastasis.

Zhong-Yu Yuan1, Rong-Zhen Luo2, Rou-Jun Peng1, Shu-Sen Wang1, Cong Xue1.   

Abstract

BACKGROUND: Triple-negative breast cancer (TNBC) is associated with poor prognosis and high probability of distant metastases. Tumor microenvironments play a pivotal role in tumor metastasis. Tumor-associated macrophages (TAMs) are one of the main cell components, and they are correlated with increasing metastatic risk. The aim of this study is to analyze the prognostic significance of the infiltration of TAMs in patients with TNBC.
MATERIALS AND METHODS: Immunohistochemical staining for cluster of differentiation (CD)68 (a marker for macrophages) was performed on tissue microarrays of operable breast cancer among 287 patients with TNBC, and the number of infiltrating TAMs was correlated with clinicopathological parameters.
RESULTS: We found that TNBC with a large number of infiltrating TAMs had a significantly higher risk of distant metastasis, as well as lower rates of disease-free survival and overall survival than those with a smaller number of infiltrating TAMs. Multivariate analysis indicated that the number of infiltrating TAMs was a significant independent prognostic factor of disease-free survival (P=0.001) in all patients.
CONCLUSION: Our results suggested that high infiltrating TAMs are a significantly unfavorable prognostic factor for patients with TNBC, and they could become a potentially useful prognostic marker for TNBC.

Entities:  

Keywords:  breast carcinoma; prognosis; triple-negative; tumor-associated macrophages

Year:  2014        PMID: 25187727      PMCID: PMC4149399          DOI: 10.2147/OTT.S61838

Source DB:  PubMed          Journal:  Onco Targets Ther        ISSN: 1178-6930            Impact factor:   4.147


Introduction

Breast cancers have been classified into distinct molecular subtypes based on deoxyribonucleic acid microarray expression profiling, which include luminal A, luminal B, human epidermal growth factor receptor-2 (HER2) overexpression, basal-like, and normal breast subtypes.1–3 These subtypes demonstrate distinctive immunohistochemical features and clinical behavior.4–6 The basal-like subtype is immunohistochemically characterized by a lack of expression of the estrogen receptor, progesterone receptor, and HER2, and it is thus also categorized as triple-negative breast cancer (TNBC). TNBC, which accounts for about 15%–20% of all breast cancers, is associated with poor prognosis and a high probability of distant metastases, especially of the lung and brain.7–10 As metastatic disease is incurable, accurate prognostic factors and more efficacious treatments are needed. Inflammatory cells have gained a renewed interest in breast cancer research due to our increased understanding of their role in tumor development. Firstly, infiltrating tumor-associated macrophages (TAMs) were initially thought to represent the host response against tumors, now evidence suggests that these cells may actually contribute to cancer development.11 Secondly, the recruitment of TAMs changes the microenvironment, which includes the enrichment of cytokines and growth factors that may encourage the proliferation of malignant cells.12 Thirdly, the cross-talk between infiltrating TAMs and the cancer cells is likely to have profound effects on tumor progression.13 Thus, infiltrating TAMs likely promote, rather than inhibit, cancer development and progression. A large number of studies also suggested that TAMs were closely associated with poor prognosis in patients with breast cancer.14–17 However, the relationship between infiltrating TAMs and the prognosis of patients with TNBC has not yet been investigated. In this study, we investigated the relationship of infiltrating TAMs with the clinicopathologic characteristics of TNBC.

Materials and methods

Patients and tissue microarrays

This study consisted of 287 female patients with TNBC diagnosed without any evidence of distant metastasis at the time of surgery, between January 2000–December 2008 at Sun Yat-sen University Cancer Center (Guangdong, People’s Republic of China). The cases selected were based on the distinctive pathologic diagnosis of invasive breast cancer, the availability of complete medical records and patients’ follow-up status, and the lack of estrogen receptor, progesterone receptor, and HER2 expression. All patients were staged according to the American Joint Committee on Cancer (AJCC 2010, seventh edition) tumor, node, metastasis (TNM) Staging System for Breast Cancer.18 In this study, the paraffin-embedded pathologic specimens were retrieved from the archives of the Department of Pathology of Sun Yat-sen University Cancer Center. Tissue microarrays were constructed as described previously.19 Each sample was arrayed in triplicate to minimize tissue loss and to overcome tumor heterogeneity. All sample donors gave written informed consent. The use of the samples involved in our study was approved by the Institute Research Medical Ethics Committee of Sun Yat-sen University.

Immunohistochemistry

Immunohistochemistry was performed for cluster of differentiation (CD)68 on tissue microarray sections. Briefly, tissue microarray slides were deparaffinized and rehydrated for 5 minutes. After microwave pretreatment in citrate buffer (pH 6.0) for antigen retrieval, the slides were immersed in 0.3% (volume/volume) hydrogen peroxide for 20 minutes to block endogenous peroxidase activity. The slides were then washed and incubated overnight at 4°C with primary antibodies against CD68 (RM-9116, rabbit, 1:100; Lab Vision, Thermo Fisher Scientific, Waltham, MA, USA). After a second incubation with biotinylated antigoat antibodies, the slides were incubated with peroxidase-labeled streptavidin. The reaction products were visualized by immersing the slides in diaminobenzidine tetrachloride and counterstaining with Harris hematoxylin.

Evaluation of immunohistochemistry

TMAs were analyzed by one of the authors (RZL). The evaluation of full-face tissue sections revealed that macrophages were observed in both tumor nest and stroma. Recently, several studies have showed that TAMs in tumor stroma, but not in tumor nest, were connected with a worse survival rate for patients with breast cancer.20 We thus counted the number of TAMs in three separate tumor stroma sites. The number of positive CD68 cells (cytoplasmic staining for macrophages) in the stroma was counted in three high-power fields (200× objective) per TMA tissue core, and then the mean number of triplicate cores from each tumor was calculated for the macrophages.

Statistical analysis

The R program maxstat (Institute for Statistics and Mathematics, Wirtschaftsuniversität Wien, Vienna, Austria) was used to find an optimal cut-off point for macrophages as a predictor of cancer recurrence. We found that sixteen macrophages per high-power field was the optimal cutoff point that provided a good separation of the time-to-recurrence curves. Then, the patients were divided into one of two groups: the TAM high-infiltration group (≥16 TAMs); and the TAM low-infiltration group (<16 TAMs). We examined the relationship between macrophages and the clinicopathologic variables by the χ test or Fisher’s exact test. The disease-free survival (DFS) rate and overall survival (OS) rate curves were estimated using the Kaplan–Meier method, and the survival differences according to CD68 expression were compared using the log-rank test. A multivariate analysis was performed using Cox’s regression model. To examine whether macrophages were an independent prognostic factor, we adjusted for age at diagnosis, tumor size, lymph node status, histological grade, and lymphovascular invasion (LVI), which were considered as traditional prognostic factors, were included in the multivariate analysis with Enter model. The hazard ratios were presented with their 95% confidence intervals. P-values ≤0.05 denote statistical significance. All analyses were performed using the statistical software, SPSS 16.0 (IBM Corporation, Armonk, NY, USA). In addition, DFS was defined as the interval from the date of operation to the date of the first recurrence. OS was calculated as the period from the date of diagnosis to the date of death. Locoregional relapse-free survival was defined as the interval from the first treatment for breast cancer to the first locoregional relapse. Distant metastasis free survival was calculated as the period from the date of diagnosis to the date of distant metastasis or the presence of contralateral breast cancer. Locoregional relapse was defined as the recurrence either in the treated breast or in the ipsilateral lymph node-bearing area (axillary, internal mammary, supraclavicular node).

Results

Association of TAMs with clinicopathologic characteristics

A total of 287 TNBC patients were grouped according to the mean number of TAMs. Among the 287 tumor specimens, 103 (35.9%) were divided into the high-infiltration group (Figure 1). The association of TAMs with the various clinicopathological parameters is listed in Table 1. TAMs were associated with lymph node involvement (P=0.007) and LVI (P=0.032). There was no significant association with age at diagnosis, tumor size, and histological grade between the two groups.
Figure 1

Representative immunohistochemical staining results for tumor-associated macrophages (marker CD68).

Notes: (A) High infiltration (100×); (B) high infiltration (200×); (C) low infiltration (100×); (D) low infiltration (200×).

Abbreviation: CD68, cluster of differentiation 68.

Table 1

Association of TAMs with various clinicopathological features

CharacteristicsHigh TAMs
Low TAMs
P-value
N%N%
N10335.918464.1
Age, years
 ≤402726.24021.70.388
 >407673.814478.3
Tumor size, cm
 ≤22625.24122.30.565
 >27774.814377.7
Node status
 Negative4139.810557.10.007*
 Positive6260.27942.9
Histological grade
 1/22322.36032.60.078
 38077.712467.4
Lymphovascular invasion
 Absent6361.213673.90.032*
 Present4038.84826.1

Note:

Statistically significant.

Abbreviations: TAM, tumor-associated macrophage; N, number.

TAMs and disease-free survival and overall survival

As of December 2013, the median follow-up time was 89 months (range: 4–181 months). Among the total of 287 patients, 106 relapsed and 72 died. The 5-year DFS and OS of all patients were 79.0% and 83.1%, respectively. When the patients were stratified in terms of infiltrating TAMs, the 8-year DFS for the TAM high-infiltration and TAM low-infiltration patients were 67.8% and 85.3%, respectively. The 5-year OS for the TAM high-infiltration and TAM low-infiltration patients were 71.1% and 89.5%, respectively (Figure 2A and B).
Figure 2

Association of TAM infiltration with the prognosis of TNBC patients.

Notes: (A) Disease-free survival; (B) overall survival; (C) locoregional relapse-free survival; (D) distant metastasis-free survival.

Abbreviations: TAM, tumor-associated macrophage; n, number; TNBC, triple-negative breast cancer.

Compared to the TAM low-infiltration patients, patients with TAM high-infiltration had a significantly higher risk for developing distant metastasis (72.1% versus 86.8%; P<0.001), whereas the risk for locoregional recurrence was not significantly different between these two groups (82.7% versus 85.1%, respectively; P=0.123) (Figure 2C and D).

Univariate and multivariate analysis

Statistically significant predictors of DFS, as observed during the univariate analysis, are listed in Table 2. Large primary tumor, positive lymph nodes, higher histological grade, present LVI, and high TAM infiltration were correlated with shorter DFS. The patients with high TAM infiltration had significantly worse outcomes in terms of DFS (P<0.001) than did the patients with low TAM infiltration. In the multivariate analysis, high TAM infiltration remained a significant predictor of DFS when entered into a model containing all of the clinicopathologic variables (P<0.001).
Table 2

Univariate and multivariate analysis of disease-free survival in the entire study population

VariablesUnivariate
Multivariate
HR95% CIP-valueHR95% CIP-value
Age, years (≤40 versus >40)0.880.59–1.310.5270.920.61–1.380.685
Tumor size, cm (≤2 versus >2)1.751.06–2.890.0191.610.97–2.680.067
Node status (negative versus positive)4.132.76–6.18<0.0012.331.44–3.790.001
Histological grade (1/2 versus 3)2.361.46–3.82<0.0011.450.89–2.380.140
Lymphovascular invasion (absent versus present)3.752.62–5.35<0.0011.991.31–3.030.001
TAM infiltration (low versus high)2.771.94–3.96<0.0012.201.53–3.16<0.001

Abbreviations: HR, hazard ratio; CI, confidence interval; TAM, tumor-associated macrophage.

Discussion

In the current study, we evaluated the prognostic significance of TAMs in patients with TNBC. We found that patients with high TAM infiltration accounted for 35.9% of 287 TNBC cases. High TAM infiltration was associated with a higher proportion of positive lymph nodes and LVI. Patients with high TAM infiltration had a significantly higher risk for developing distant metastasis and poor OS and DFS. Multivariate analysis showed that TAM infiltration was an independent predictor of poor DFS among TNBC patients. Over the past few years, a growing amount of evidence has shown that the tumor microenvironment, which is mainly composed of leukocytes, vascular cells, and fibroblasts, plays a pivotal role in tumor progression and metastasis.21,22 In the tumor microenvironment, infiltrating leukocytes were recently suggested to play a key role in breast cancer.23 TAMs make up the majority of infiltrating leukocytes. It has been suggested that high TAM infiltration is correlated with increasing metastatic risk and poor prognosis in breast cancer.24–27 A meta-analysis showed that in >80% of cases, increased macrophage density was associated with poor prognosis.28 However, it was particularly noteworthy that the infiltration of macrophages was mainly associated with hormone receptor negativity and basal phenotype.20,29 These results suggested that TAM infiltration might be more closely associated with TNBC. The mechanism underlying TAM’s ability to influence cancer progression and metastasis remains unclear. In the tumor microenvironment, macrophages are derived from circulating monocytes.30 Several cytokines have been implicated in the recruitment of macrophages into the tumors.28 In turn, TAMs produce a variety of cytokines and chemokines, as well as growth factors for both the epithelial and endothelial cells, which play a vital role in tumor growth and metastasis.12,31

Conclusion

TAM infiltration might serve as a prognostic indicator for poor outcomes among patients with TNBC. Perhaps more importantly, these cells may serve as potential cellular targets for novel therapeutic interventions.
  30 in total

Review 1.  Triple-negative breast cancer.

Authors:  William D Foulkes; Ian E Smith; Jorge S Reis-Filho
Journal:  N Engl J Med       Date:  2010-11-11       Impact factor: 91.245

2.  Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.

Authors:  David G DeNardo; Donal J Brennan; Elton Rexhepaj; Brian Ruffell; Stephen L Shiao; Stephen F Madden; William M Gallagher; Nikhil Wadhwani; Scott D Keil; Sharfaa A Junaid; Hope S Rugo; E Shelley Hwang; Karin Jirström; Brian L West; Lisa M Coussens
Journal:  Cancer Discov       Date:  2011-06-01       Impact factor: 39.397

Review 3.  Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics.

Authors:  Rita A Mukhtar; Onouwem Nseyo; Michael J Campbell; Laura J Esserman
Journal:  Expert Rev Mol Diagn       Date:  2011-01       Impact factor: 5.225

Review 4.  Distinct role of macrophages in different tumor microenvironments.

Authors:  Claire E Lewis; Jeffrey W Pollard
Journal:  Cancer Res       Date:  2006-01-15       Impact factor: 12.701

5.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

6.  Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.

Authors:  Torsten O Nielsen; Forrest D Hsu; Kristin Jensen; Maggie Cheang; Gamze Karaca; Zhiyuan Hu; Tina Hernandez-Boussard; Chad Livasy; Dave Cowan; Lynn Dressler; Lars A Akslen; Joseph Ragaz; Allen M Gown; C Blake Gilks; Matt van de Rijn; Charles M Perou
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

7.  Elevated serum levels of vascular endothelial growth factor are associated with tumor-associated macrophages in primary breast cancer.

Authors:  Luis Vicioso; Francisco J Gonzalez; Martina Alvarez; Nuria Ribelles; Manuel Molina; Antonia Marquez; Lidia Perez; Alfredo Matilla; Emilio Alba
Journal:  Am J Clin Pathol       Date:  2006-01       Impact factor: 2.493

Review 8.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

9.  Tumor microenvironment of metastasis in human breast carcinoma: a potential prognostic marker linked to hematogenous dissemination.

Authors:  Brian D Robinson; Gabriel L Sica; Yi-Fang Liu; Thomas E Rohan; Frank B Gertler; John S Condeelis; Joan G Jones
Journal:  Clin Cancer Res       Date:  2009-03-24       Impact factor: 12.531

10.  Repeated observation of breast tumor subtypes in independent gene expression data sets.

Authors:  Therese Sorlie; Robert Tibshirani; Joel Parker; Trevor Hastie; J S Marron; Andrew Nobel; Shibing Deng; Hilde Johnsen; Robert Pesich; Stephanie Geisler; Janos Demeter; Charles M Perou; Per E Lønning; Patrick O Brown; Anne-Lise Børresen-Dale; David Botstein
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-26       Impact factor: 12.779

View more
  64 in total

Review 1.  The lymphatic system and pancreatic cancer.

Authors:  Darci M Fink; Maria M Steele; Michael A Hollingsworth
Journal:  Cancer Lett       Date:  2015-12-29       Impact factor: 8.679

2.  The MicroRNA miR-210 Is Expressed by Cancer Cells but Also by the Tumor Microenvironment in Triple-Negative Breast Cancer.

Authors:  Isabelle Bar; Ahmad Merhi; Fadi Abdel-Sater; Abduelhakem Ben Addi; Sara Sollennita; Jean-Luc Canon; Paul Delrée
Journal:  J Histochem Cytochem       Date:  2017-04-12       Impact factor: 2.479

Review 3.  Progress in tumor-associated macrophage (TAM)-targeted therapeutics.

Authors:  Chayanon Ngambenjawong; Heather H Gustafson; Suzie H Pun
Journal:  Adv Drug Deliv Rev       Date:  2017-04-25       Impact factor: 15.470

4.  Isolation of Mouse and Human Tumor-Associated Macrophages.

Authors:  Luca Cassetta; Roy Noy; Agnieszka Swierczak; Gaël Sugano; Harriet Smith; Lisa Wiechmann; Jeffrey W Pollard
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

Review 5.  Tumor-associated macrophages: Role in the pathological process of tumorigenesis and prospective therapeutic use (Review).

Authors:  Olga V Zhukova; Tatiana F Kovaleva; Evgenia V Arkhipova; Sergey A Ryabov; Irina V Mukhina
Journal:  Biomed Rep       Date:  2020-08-28

Review 6.  Tumor microenvironment promotes breast cancer chemoresistance.

Authors:  Umar Mehraj; Abid Hamid Dar; Nissar A Wani; Manzoor A Mir
Journal:  Cancer Chemother Pharmacol       Date:  2021-01-09       Impact factor: 3.333

7.  Loss of ELF5-FBXW7 stabilizes IFNGR1 to promote the growth and metastasis of triple-negative breast cancer through interferon-γ signalling.

Authors:  Sushil Kumar; Ratnesh Kumar Srivastava; Snahlata Singh; Ajeya Nandi; Gatha Thacker; Hemma Murali; Sabrina Kim; Mary Baldeon; John Tobias; Mario Andres Blanco; Rizwan Saffie; M Raza Zaidi; Satrajit Sinha; Luca Busino; Serge Y Fuchs; Rumela Chakrabarti
Journal:  Nat Cell Biol       Date:  2020-04-13       Impact factor: 28.824

Review 8.  Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers.

Authors:  Irina Larionova; Gulnara Tuguzbaeva; Anastasia Ponomaryova; Marina Stakheyeva; Nadezhda Cherdyntseva; Valentin Pavlov; Evgeniy Choinzonov; Julia Kzhyshkowska
Journal:  Front Oncol       Date:  2020-10-22       Impact factor: 6.244

9.  Zoledronic Acid-containing Nanoparticles With Minimum Premature Release Show Enhanced Activity Against Extraskeletal Tumor.

Authors:  Xu Li; Solange A Valdes; Riyad F Alzhrani; Stephanie Hufnagel; Stephen D Hursting; Zhengrong Cui
Journal:  ACS Appl Mater Interfaces       Date:  2019-02-11       Impact factor: 9.229

10.  Pretreatment lymphocyte to monocyte ratio as a predictor of prognosis in patients with early-stage triple-negative breast cancer.

Authors:  Juanjuan He; Pengwei Lv; Xue Yang; Yanli Chen; Chao Liu; Xinguang Qiu
Journal:  Tumour Biol       Date:  2016-01-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.